Louis Navellier’s #1 Stock for 2022

On October 20, the man who recommended Google before anyone else will reveal his #1 stock pick for 2022 — for FREE — ticker symbol and all — in a special presentation.

Wed, October 20 at 4:00PM ET
 
 
 
 

5 Biotechnology Stocks to Buy Now

This week, 5 Biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

Genomic Health, Inc. (GHDX) is seeing ratings go up from a C last week to a B this week. Genomic Health, Inc. is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. The company also gets A’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of GHDX stock.

Cytokinetics, Incorporated’s (CYTK) ratings are looking better this week, moving up to a A from last week’s B. Cytokinetics, Incorporated is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of CYTK stock.

This is a strong week for Achillion Pharmaceuticals, Inc. (ACHN). The company’s rating climbs to B from the previous week’s C. Achillion Pharmaceuticals, Inc. focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. For more information, get Portfolio Grader’s complete analysis of ACHN stock.

Nexvet Biopharma PLC (NVET) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of NVET stock.

This week, Sophiris Bio Inc.’s (SPHS) ratings are up from a B last week to a A. The company also gets A’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of SPHS stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/07/5-biotechnology-stocks-to-buy-now-4/.

©2021 InvestorPlace Media, LLC